TY - JOUR
T1 - Design and Implementation of a National Program to Monitor the Prevalence of SARS-CoV-2 IgG Antibodies in England Using Self-Testing
T2 - The REACT-2 Study
AU - Ward, Helen
AU - Atchison, Christina
AU - Whitaker, Matthew
AU - Davies, Bethan
AU - Ashby, Deborah
AU - Darzi, Ara
AU - Chadeau-Hyam, Marc
AU - Riley, Steven
AU - Donnelly, Christl
AU - Barclay, Wendy
AU - Cooke, Graham
AU - Elliott, Paul
N1 - Publisher Copyright:
© 2023 American Public Health Association Inc.. All rights reserved.
PY - 2023/11
Y1 - 2023/11
N2 - Data System. The UK Department of Health and Social Care funded the REal-time Assessment of Community Transmission-2 (REACT-2) study to estimate community prevalence of SARS-CoV-2 IgG (immunoglobulin G) antibodies in England. Data Collection/Processing. We obtained random cross-sectional samples of adults from the National Health Service (NHS) patient list (near-universal coverage). We sent participants a lateral flow immunoassay (LFIA) self-test, and they reported the result online. Overall, 905 991 tests were performed (28.9% response) over 6 rounds of data collection (June 2020–May 2021). Data Analysis/Dissemination. We produced weighted estimates of LFIA test positivity (validated against neutralizing antibodies), adjusted for test performance, at local, regional, and national levels and by age, sex, and ethnic group and area-level deprivation score. In each round, fieldwork occurred over 2 weeks, with results reported to policymakers the following week. We disseminated results as preprints and peer-reviewed journal publications. Public Health Implications. REACT-2 estimated the scale and variation in antibody prevalence over time.
AB - Data System. The UK Department of Health and Social Care funded the REal-time Assessment of Community Transmission-2 (REACT-2) study to estimate community prevalence of SARS-CoV-2 IgG (immunoglobulin G) antibodies in England. Data Collection/Processing. We obtained random cross-sectional samples of adults from the National Health Service (NHS) patient list (near-universal coverage). We sent participants a lateral flow immunoassay (LFIA) self-test, and they reported the result online. Overall, 905 991 tests were performed (28.9% response) over 6 rounds of data collection (June 2020–May 2021). Data Analysis/Dissemination. We produced weighted estimates of LFIA test positivity (validated against neutralizing antibodies), adjusted for test performance, at local, regional, and national levels and by age, sex, and ethnic group and area-level deprivation score. In each round, fieldwork occurred over 2 weeks, with results reported to policymakers the following week. We disseminated results as preprints and peer-reviewed journal publications. Public Health Implications. REACT-2 estimated the scale and variation in antibody prevalence over time.
UR - http://www.scopus.com/inward/record.url?scp=85173604063&partnerID=8YFLogxK
U2 - 10.2105/AJPH.2023.307381
DO - 10.2105/AJPH.2023.307381
M3 - Article
C2 - 37733993
AN - SCOPUS:85173604063
SN - 0090-0036
VL - 113
SP - 1201
EP - 1209
JO - American Journal of Public Health
JF - American Journal of Public Health
IS - 11
ER -
